PAGE Therapeutics Overview
- Year Founded
-
2022
- Status
-
Private
- Employees
-
6
- Latest Deal Type
-
Series A
- (Cancelled)
- Latest Deal Amount
-
$50M
- Investors
-
4
PAGE Therapeutics General Information
Description
Operator of a platform-based oncology drug development company intended to discover and commercialize anti-metastatic compounds. The company works on the discovery, development, and commercialization of innovative compounds, enabling the oncology market to prevent the formation of new metastases in cancer patients with solid tumours.
Contact Information
Website
www.pagetherapeutics.comCorporate Office
- Aeschenvorstadt 48
- 4051 Basel
- Switzerland
Corporate Office
- Aeschenvorstadt 48
- 4051 Basel
- Switzerland
PAGE Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 3. Early Stage VC (Series A) | 15-May-2023 | $50M | Cancelled | Pre-Clinical Trials | ||
| 2. Early Stage VC | 17-Mar-2023 | Completed | Generating Revenue | |||
| 1. University Spin-Out | 01-Jan-2022 | Completed | Startup |
PAGE Therapeutics Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series S Preference |
PAGE Therapeutics Patents
PAGE Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026119971-A1 | Bufadienolide compounds substituted by a nitrogen heterocycle | Pending | 03-Dec-2024 | ||
| WO-2026119973-A1 | Novel compounds | Pending | 03-Dec-2024 |
PAGE Therapeutics Signals
PAGE Therapeutics Investors (4)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Claris Ventures | Venture Capital | Minority | ||
| Kizoo Technology Capital | Venture Capital | Minority | ||
| XGEN Venture | Impact Investing | Minority | ||
| ETH Zurich | University |
PAGE Therapeutics FAQs
-
When was PAGE Therapeutics founded?
PAGE Therapeutics was founded in 2022.
-
Where is PAGE Therapeutics headquartered?
PAGE Therapeutics is headquartered in Basel, Switzerland.
-
What is the size of PAGE Therapeutics?
PAGE Therapeutics has 6 total employees.
-
What industry is PAGE Therapeutics in?
PAGE Therapeutics’s primary industry is Drug Discovery.
-
Is PAGE Therapeutics a private or public company?
PAGE Therapeutics is a Private company.
-
What is PAGE Therapeutics’s current revenue?
The current revenue for PAGE Therapeutics is .
-
How much funding has PAGE Therapeutics raised over time?
PAGE Therapeutics has raised $4.29M.
-
Who are PAGE Therapeutics’s investors?
Claris Ventures, Kizoo Technology Capital, XGEN Venture, and ETH Zurich have invested in PAGE Therapeutics.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process